EGFR and non-small cell lung carcinoma: However, no retrospective study has yet definitively compared which is better in terms of survival prolongation in NSCLC patients after EGFR-TKIs resistance between immune-related combination therapies and chemotherapy + antiangiogenic therapy which is commonly used in the clinic.